A Surgeon in London Removed a Man's Prostate From 1,500 Miles Away
Dr. Dereck Mush, MD, MBA
Multiply Labs
Robotic clusters that automate cell and gene therapy and other biologics manufacturing inside existing cleanrooms.
What they do
Multiply Labs builds enclosed, GMP compliant robotic clusters that plug into a manufacturer's existing instruments and validated processes. The company reports a 74% reduction in cost per dose and up to 100 times the throughput of manual work. In October 2026 it raised a $75M Series B led by Dr. Patrick Soon-Shiong and NantWorks, bringing total funding past $100M.
The record
- Vertical
- Biotech & Therapeutics
- Sub-segment
- Robotic biomanufacturing
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- San Francisco, United States
- Region
- North America
- Founded
- 2016
- Total funding
- $100M raised
Notable investors: NantWorks, AstraZeneca, Teradyne, Lingotto, Lux Capital, Founders Fund, Casdin Capital.
Also in Biotech & Therapeutics
Related on The Signal
Dr. Dereck Mush, MD, MBA
The biotech IPO window is reopening, cautiously, and the terms have changed
Dr. Dereck Mush, MD, MBA
CDMOs race to add capacity as cell and gene therapy demand outpaces supply
Dr. Dereck Mush, MD, MBA
Synthetic CT and Radiation-Free Orthopedics: The Economics of Single-Modality MRI Surgical Workflows
Dr. Dereck Mush, MD, MBA